CoChat
Sign Up
Cited by 31Amyotrophic Lateral Sclerosis ResearchNutrition and Health in AgingAmyloidosis: Diagnosis, Treatment, Outcomes

Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles

Open access
Goutman, Stephen A., Boss, Jonathan, Iyer, Gayatri, Habra, Hani, Savelieff, Masha G., Karnovsky, Alla, Mukherjee, Bhramar, Feldman, Eva L.·2023·Muscle & Nerve
DOI 10.1002/mus.27744PMC PMC9957813
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction/Aims: Body mass index (BMI) is linked to amyotrophic lateral sclerosis (ALS) risk and prognosis, but additional research is needed. The aim of this study was to identify whether and when historical changes in BMI occurred in ALS participants, how these longer term trajectories associated with survival, and whether metabolomic profiles provided insight into potential mechanisms. Methods: ALS and control participants self‐reported body height and weight 10 (reference) and 5 years earlier, and at study entry (diagnosis for ALS participants). Generalized estimating equations evaluated differences in BMI trajectories between cases and controls. ALS survival was evaluated by BMI trajectory group using accelerated failure time models. BMI trajectories and survival associations were explored using published metabolomic profiling and correlation networks. Results: Ten‐year BMI trends differed between ALS and controls, with BMI loss in the 5 years before diagnosis despite BMI gains 10 to 5 years beforehand in both groups. An overall 10‐year drop in BMI associated with a 27.1% decrease in ALS survival (P = .010). Metabolomic networks in ALS participants showed dysregulation in sphingomyelin, bile acid, and plasmalogen subpathways. Discussion: ALS participants lost weight in the 5‐year period before enrollment. BMI trajectories had three distinct groups and the group with significant weight loss in the past 10 years had the worst survival. Participants with a high BMI and increase in weight in the 10 years before symptom onset also had shorter survival. Certain metabolomics profiles were associated with the BMI trajectories. Replicating these findings in prospective cohorts is warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mus.27744

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 59

  1. [2]Goutman SA, Hardiman O, Al-Chalabi A, Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology. May 2022; 21(5): 465– 479. doi: 10.1016/S1474-4422(21)00414-2 35334234 PMC9513754 · DOI
  2. [3]Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & frontotemporal degeneration. Aug 2019; 20(5–6): 303– 309. doi: 10.1080/21678421.2019.1587634 30892087 PMC6613999 · DOI
  3. [4]Moglia C, Calvo A, Grassano M, Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. Jun 2019; 90(6): 666– 673. doi: 10.1136/jnnp-2018-319611 30630957 · DOI
  4. [5]Peter RS, Rosenbohm A, Dupuis L, Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. Oct 2017; 32(10): 901– 908. doi: 10.1007/s10654-017-0318-z 28975435 · DOI · Paper page
  5. [6]Nakken O, Meyer HE, Stigum H, Holmoy T. High BMI is associated with low ALS risk: A population-based study. Neurology. Jul 30 2019; 93(5): e424– e432. doi: 10.1212/WNL.0000000000007861 31243073 · DOI · Paper page
  6. [7]O’Reilly ÉJ, Wang H, Weisskopf MG, Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. Apr 2013; 14(3): 205– 11. doi: 10.3109/21678421.2012.735240 23134505 PMC3615420 · DOI
  7. [8]O’Reilly EJ, Wang M, Adami HO, Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotrophic lateral sclerosis & frontotemporal degeneration. Aug 2018; 19(5–6): 396– 406. doi: 10.1080/21678421.2018.1452944 29658324 PMC6423444 · DOI
  8. [9]Mariosa D, Beard JD, Umbach DM, Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. Am J Epidemiol. Mar 1 2017; 185(5): 362– 371. doi: 10.1093/aje/kww140 28158443 PMC5860019 · DOI · Paper page
  9. [10]Gallo V, Wark PA, Jenab M, Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. Feb 26 2013; 80(9): 829– 38. doi: 10.1212/WNL.0b013e3182840689 23390184 PMC3598455 · DOI
  10. [11]Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ. Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression. Neuro-degenerative diseases. 2016; 16(5–6): 382– 97. doi: 10.1159/000446502 27400276 · DOI
  11. [12]Steyn FJ, Ioannides ZA, van Eijk RPA, Hypermetabolism in ALS is associated with greater functional decline and shorter survival. Journal of neurology, neurosurgery, and psychiatry. Oct 2018; 89(10): 1016– 1023. doi: 10.1136/jnnp-2017-317887 29706605 PMC6166607 · DOI
  12. [13]Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. The Lancet Neurology. Jan 2011; 10(1): 75– 82. doi: 10.1016/S1474-4422(10)70224-6 21035400 · DOI
  13. [14]Mariosa D, Hammar N, Malmstrom H, Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Annals of neurology. May 2017; 81(5): 718– 728. doi: 10.1002/ana.24936 28437840 · DOI
  14. [15]Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. Apr 28 2020; 94(17): e1835– e1844. doi: 10.1212/WNL.0000000000009322 32221024 PMC7274849 · DOI
  15. [16]Cirulli ET, Guo L, Leon Swisher C, Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. Cell Metab. Feb 5 2019; 29(2): 488– 500.e2. doi: 10.1016/j.cmet.2018.09.022 30318341 PMC6370944 · DOI
  16. [17]Ho JE, Larson MG, Ghorbani A, Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One. 2016; 11(2): e0148361. doi: 10.1371/journal.pone.0148361 26863521 PMC4749349 · DOI
  17. [18]Kraus WE, Pieper CF, Huffman KM, Association of Plasma Small-Molecule Intermediate Metabolites With Age and Body Mass Index Across Six Diverse Study Populations. J Gerontol A Biol Sci Med Sci. Nov 2016; 71(11): 1507– 1513. doi: 10.1093/gerona/glw031 26984390 PMC6279215 · DOI
  18. [19]Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, and psychiatry. Aug 2019; 90(8): 907– 912. doi: 10.1136/jnnp-2018-319785 30760645 PMC6625908 · DOI
  19. [20]Su FC, Goutman SA, Chernyak S, Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA neurology. Jul 1 2016; 73(7): 803– 11. doi: 10.1001/jamaneurol.2016.0594 27159543 PMC5032145 · DOI
  20. [21]Yu Y, Su FC, Callaghan BC, Goutman SA, Batterman SA, Feldman EL. Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in Michigan. PloS one. Jun 30 2014; 9(6): e101186. doi: ARTN e101186 10.1371/journal.pone.0101186 24979055 PMC4076303 · DOI
  21. [22]Goutman SA, Boss J, Godwin C, Mukherjee B, Feldman EL, Batterman SA. Associations of self-reported occupational exposures and settings to ALS: a case-control study. Int Arch Occup Environ Health. Sep 2022; 95(7): 1567– 1586. doi: 10.1007/s00420-022-01874-4 35593931 PMC9424174 · DOI
  22. [23]Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. Dec 2000; 1(5): 293– 9. doi: 10.1080/146608200300079536 11464847 · DOI · Paper page
  23. [24]Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. Jul 1 1972; 25(6): 329– 43. doi: 10.1016/0021-9681(72)90027-6 4650929 · DOI
  24. [25]Goutman SA, Boss J, Guo K, Untargeted metabolomics yields insight into ALS disease mechanisms. Journal of neurology, neurosurgery, and psychiatry. Dec 2020; 91(12): 1329– 1338. doi: 10.1136/jnnp-2020-323611 32928939 PMC7677469 · DOI
  25. [26]Goutman SA, Guo K, Savelieff MG, Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain: a journal of neurology. Jan 28 2022;doi: 10.1093/brain/awac025 PMC9762943 35088843 · DOI
  26. [27]Liang KY, Zeger SL. Longitudinal Data-Analysis Using Generalized Linear-Models. Biometrika. Apr 1986; 73(1): 13– 22. doi:DOI 10.1093/biomet/73.1.13 · DOI · Paper page
  27. [28]Halekoh U, Højsgaard S, Yan J. TheRPackagegeepackfor Generalized Estimating Equations. Journal of Statistical Software. 12/22 2006; 15(2): 1– 11. doi: 10.18637/jss.v015.i02 · DOI
  28. [29]Genolini C, Alacoque X, Sentenac M, Arnaud C. kml and kml3d: R Packages to Cluster Longitudinal Data. 2015. 2015-06-01 2015; 65(4): 34. doi: 10.18637/jss.v065.i04 · DOI
  29. [30]Calinski T, Harabasz J. A dendrite method for cluster analysis. Communications in Statistics - Theory and Methods. 1974/01/01 1974; 3(1): 1– 27. doi: 10.1080/03610927408827101 · DOI
  30. [31]Gower JC. Some Distance Properties of Latent Root and Vector Methods Used in Multivariate Analysis. Biometrika. 1966; 53(3/4): 325– &. doi:DOI 10.1093/biomet/53.3-4.325 · DOI
  31. [32]Basu S, Duren W, Evans CR, Burant CF, Michailidis G, Karnovsky A. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. Bioinformatics. May 15 2017; 33(10): 1545– 1553. doi: 10.1093/bioinformatics/btx012 28137712 PMC5860222 · DOI
  32. [33]Iyer GR, Wigginton J, Duren W, Application of Differential Network Enrichment Analysis for Deciphering Metabolic Alterations. Metabolites. Nov 24 2020; 10(12)doi: 10.3390/metabo10120479 PMC7761243 33255384 · DOI
  33. [34]Ma J, Karnovsky A, Afshinnia F, Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics. Sep 15 2019; 35(18): 3441– 3452. doi: 10.1093/bioinformatics/btz114 30887029 PMC6748777 · DOI
  34. [35]Lancichinetti A, Fortunato S. Consensus clustering in complex networks. Sci Rep. 2012/03/27 2012; 2(1): 336. doi: 10.1038/srep00336 22468223 PMC3313482 · DOI
  35. [36]Friedman J, Hastie T, Tibshirani R. A Note on the Group Lasso and a Sparse Group Lasso. arXiv:10010736. 01/05 2010; 22
  36. [37]Huisman MH, Seelen M, van Doormaal PT, Effect of Presymptomatic Body Mass Index and Consumption of Fat and Alcohol on Amyotrophic Lateral Sclerosis. JAMA neurology. Oct 2015; 72(10): 1155– 62. doi: 10.1001/jamaneurol.2015.1584 26280944 · DOI
  37. [38]Westeneng HJ, van Veenhuijzen K, van der Spek RA, Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. The Lancet Neurology. May 2021; 20(5): 373– 384. doi: 10.1016/S1474-4422(21)00042-9 33894192 · DOI · Paper page
  38. [39]Janse van Mantgem MR, van Eijk RPA, van der Burgh HK, Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. Aug 2020; 91(8): 867– 875. doi: 10.1136/jnnp-2020-322909 32576612 · DOI · Paper page
  39. [40]Nakamura R, Kurihara M, Ogawa N, Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci Rep. Sep 9 2021; 11(1): 17943. doi: 10.1038/s41598-021-97196-5 34504168 PMC8429558 · DOI
  40. [41]Jésus P, Fayemendy P, Nicol M, Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. Jan 2018; 25(1): 97– 104. doi: 10.1111/ene.13468 28940704 · DOI
  41. [42]Bjornevik K, Zhang Z, O’Reilly ÉJ, Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. Apr 30 2019; 92(18): e2089– e2100. doi: 10.1212/wnl.0000000000007401 30926684 PMC6512888 · DOI
  42. [43]Lawton KA, Brown MV, Alexander D, Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotrophic lateral sclerosis & frontotemporal degeneration. Sep 2014; 15(5–6): 362– 70. doi: 10.3109/21678421.2014.908311 24984169 · DOI
  43. [44]Lawton KA, Cudkowicz ME, Brown MV, Biochemical alterations associated with ALS. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. Jan 2012; 13(1): 110– 8. doi: 10.3109/17482968.2011.619197 22117131 · DOI
  44. [45]Sol J, Jové M, Povedano M, Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021; 3(3): fcab143. doi: 10.1093/braincomms/fcab143 34396104 PMC8361390 · DOI
  45. [46]Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Annals of neurology. Oct 2002; 52(4): 448– 57. doi: 10.1002/ana.10312 12325074 · DOI
  46. [47]Wang G, Bieberich E. Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul. Dec 2018; 70: 51– 64. doi: 10.1016/j.jbior.2018.09.013 30287225 PMC6251739 · DOI
  47. [48]Mohassel P, Donkervoort S, Lone MA, Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med. Jul 2021; 27(7): 1197– 1204. doi: 10.1038/s41591-021-01346-1 34059824 PMC9309980 · DOI
  48. [49]Di Ciaula A, Garruti G, Lunardi Baccetto R, Bile Acid Physiology. Ann Hepatol. Nov 2017; 16(Suppl. 1: s3-105.): s4– s14. doi: 10.5604/01.3001.0010.5493 29080336 · DOI
  49. [50]Paganoni S, Macklin EA, Hendrix S, Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. The New England journal of medicine. Sep 3 2020; 383(10): 919– 930. doi: 10.1056/NEJMoa1916945 32877582 PMC9134321 · DOI · Paper page
  50. [51]Paganoni S, Hendrix S, Dickson SP, Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle & nerve. Jan 2021; 63(1): 31– 39. doi: 10.1002/mus.27091 33063909 PMC7820979 · DOI · Paper page
  51. [52]Parry GJ, Rodrigues CM, Aranha MM, Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. Jan-Feb 2010; 33(1): 17– 21. doi: 10.1097/WNF.0b013e3181c47569 19935406 · DOI
  52. [53]Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. Feb 2012; 27(2): 200– 6. doi: 10.3346/jkms.2012.27.2.200 22323869 PMC3271295 · DOI
  53. [54]Blasco H, Veyrat-Durebex C, Bocca C, Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep. Dec 15 2017; 7(1): 17652. doi: 10.1038/s41598-017-17389-9 29247199 PMC5732162 · DOI
  54. [55]Chang KH, Lin CN, Chen CM, Altered Metabolic Profiles of the Plasma of Patients with Amyotrophic Lateral Sclerosis. Biomedicines. Dec 18 2021; 9(12)doi: 10.3390/biomedicines9121944 PMC8699018 34944760 · DOI
  55. [56]van Eunen K, Simons SM, Gerding A, Biochemical competition makes fatty-acid β-oxidation vulnerable to substrate overload. PLoS Comput Biol. 2013; 9(8): e1003186. doi: 10.1371/journal.pcbi.1003186 23966849 PMC3744394 · DOI
  56. [57]Lee I, Kazamel M, McPherson T, Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy x-ray absorptiometry in a prospective study. PLoS One. 2021; 16(5): e0251087. doi: 10.1371/journal.pone.0251087 33956876 PMC8101939 · DOI
  57. [58]Li C, Ou R, Wei Q, Shang H. Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol Aging. Jun 2021; 102: 211 e1– 211 e9. doi: 10.1016/j.neurobiolaging.2021.01.023 33640203 · DOI
  58. [59]Zhang L, Tang L, Huang T, Fan D. Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. Annals of neurology. Mar 2020; 87(3): 434– 441. doi: 10.1002/ana.25671 31916305 · DOI
  59. [60]Fernihough A, McGovern ME. Physical stature decline and the health status of the elderly population in England. Econ Hum Biol. Jan 2015; 16: 30– 44. doi: 10.1016/j.ehb.2013.12.010 24508050 PMC4103973 · DOI

Cited by

Sorted by citations

Authors
Goutman, S. A., Boss, J., Iyer, G., Habra, H., Savelieff, M. G., Karnovsky, A., Mukherjee, B., & Feldman, E. L.
Affiliations
University of Michigan (US)
Corresponding author
Goutman, Stephen A.
ORCID
Venue
Muscle & Nerve
Publisher
Wiley
Published
2022-11-18
Volume
67
Issue
3
Pages
208-216
ISSN
  • 0148-639X (ISSN-L)
  • 1097-4598
DOI
10.1002/mus.27744
PMC
PMC9957813
OpenAlex
W4307921448
Cited by
31
References
1
Citations by year
2026: 8 · 2025: 9 · 2024: 6 · 2023: 8
FWCI
3.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Muscle & Nerve (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
Funders
  • Centers for Disease Control and Prevention (200‐2013‐56856, R01TS000289)
  • National Center for Advancing Translational Sciences (UL1TR002240)
  • National Institute of Environmental Health Sciences (K23ES027221, R01ES030049)
  • National Institute of Neurological Disorders and Stroke (R01NS127188)
  • Sinai Medical Staff Foundation
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
Keywords
amyotrophic lateral sclerosis, body mass index, BMI trajectories, weight loss, survival, metabolite profiles, sphingomyelin, bile acids, plasmalogens, prognosis
MeSH terms
Amyotrophic Lateral Sclerosis, Humans, Prognosis, Prospective Studies, Body Mass Index, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review